{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:17:56Z","timestamp":1793146676485,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:00:00Z","timestamp":1714608000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1007\/s11523-024-01058-9","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T06:01:45Z","timestamp":1714629705000},"page":"435-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["Emerging Toxicities of Antibody-Drug Conjugates for Breast Cancer: Clinical Prioritization of Adverse Events from the FDA Adverse Event Reporting System"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0656-7521","authenticated-orcid":false,"given":"Sara","family":"Cecco","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Puligheddu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Fusaroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Gerratana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Zamagni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrizio","family":"De Ponti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"1058_CR1","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","volume":"397","author":"S Loibl","year":"2021","unstructured":"Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. Lancet. 2021;397:1750\u201369. https:\/\/doi.org\/10.1016\/S0140-6736(20)32381-3.","journal-title":"Lancet"},{"key":"1058_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet C, Reichert JM, Senter PD, Lambert JM, Beck A. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2023;22:641\u201361. https:\/\/doi.org\/10.1038\/s41573-023-00709-2.","journal-title":"Nat Rev Drug Discov"},{"key":"1058_CR3","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.breast.2022.10.016","volume":"66","author":"E Rassy","year":"2022","unstructured":"Rassy E, Rached L, Pistilli B. Antibody drug conjugates targeting HER2: clinical development in metastatic breast cancer. Breast. 2022;66:217\u201326. https:\/\/doi.org\/10.1016\/j.breast.2022.10.016.","journal-title":"Breast"},{"key":"1058_CR4","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","volume":"367","author":"S Verma","year":"2012","unstructured":"Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367:1783\u201391. https:\/\/doi.org\/10.1056\/NEJMoa1209124.","journal-title":"N Engl J Med"},{"key":"1058_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa1814017","volume":"380","author":"G von Minckwitz","year":"2019","unstructured":"von Minckwitz G, Huang CS, Mano MS, Loibl S, Mamounas EP, Untch M, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617\u201328. https:\/\/doi.org\/10.1056\/NEJMoa1814017.","journal-title":"N Engl J Med"},{"key":"1058_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","volume":"386","author":"J Cort\u00e9s","year":"2022","unstructured":"Cort\u00e9s J, Kim SB, Chung WP, Im S, Park YH, Hegg R, et al. Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. N Engl J Med. 2022;386:1143\u201354. https:\/\/doi.org\/10.1056\/NEJMoa2115022.","journal-title":"N Engl J Med"},{"key":"1058_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387:9\u201320. https:\/\/doi.org\/10.1056\/NEJMoa2203690.","journal-title":"N Engl J Med"},{"key":"1058_CR8","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2023.01.005","volume":"67","author":"I Schlam","year":"2023","unstructured":"Schlam I, Tolaney SM, Tarantino P. How I treat HER2-low advanced breast cancer. Breast. 2023;67:116\u201323. https:\/\/doi.org\/10.1016\/j.breast.2023.01.005.","journal-title":"Breast"},{"key":"1058_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0096993","volume":"9","author":"F Ambrogi","year":"2014","unstructured":"Ambrogi F, Fornili M, Boracchi P, Trerotola M, Relli V, SImeone P, et al. Trop-2 is a determinant of breast cancer survival. PLoS\u00a0One. 2014;9: e96993. https:\/\/doi.org\/10.1371\/journal.pone.0096993.","journal-title":"PLoS\u00a0One"},{"key":"1058_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","volume":"384","author":"A Bardia","year":"2021","unstructured":"Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529\u201341. https:\/\/doi.org\/10.1056\/NEJMoa2028485.","journal-title":"N Engl J Med"},{"key":"1058_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01245-X","author":"HS Rugo","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F, Cort\u00e9s J, Schmid P, Loirat D, et al. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet. 2023;402(10411):1423-33. https:\/\/doi.org\/10.1016\/S0140-6736(23)01245-X.","journal-title":"Lancet"},{"key":"1058_CR12","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1038\/s41591-023-02478-2","volume":"29","author":"F Mosele","year":"2023","unstructured":"Mosele F, Deluche E, Lusque A, Le Bescond L, FIlleron T, Pradat Y, et al. Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trial. Nat Med. 2023;29:2110\u201320. https:\/\/doi.org\/10.1038\/s41591-023-02478-2.","journal-title":"Nat Med"},{"key":"1058_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","volume":"20","author":"P Tarantino","year":"2023","unstructured":"Tarantino P, Ricciuti B, Pradhan SM, Tolaney SM. Optimizing the safety of antibody-drug conjugates for patients with solid tumours. Nat Rev Clin Oncol. 2023;20:558\u201376. https:\/\/doi.org\/10.1038\/s41571-023-00783-w.","journal-title":"Nat Rev Clin Oncol"},{"key":"1058_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1002\/cncr.34507","volume":"129","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Liu K, Wang K, Zhu H. Treatment-related adverse events of antibody-drug conjugates in clinical trials: a systematic review and meta-analysis. Cancer. 2023;129:283\u201395. https:\/\/doi.org\/10.1002\/cncr.34507.","journal-title":"Cancer"},{"key":"1058_CR15","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Target Oncol. 2020;15:449\u201366. https:\/\/doi.org\/10.1007\/s11523-020-00738-6.","journal-title":"Target Oncol"},{"key":"1058_CR16","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1007\/s40264-022-01246-4","volume":"45","author":"C Gastaldon","year":"2022","unstructured":"Gastaldon C, Schoretsanitis G, Arzenton E, Raschi E, Papola D, Ostuzzi G, et al. Withdrawal syndrome following discontinuation of 28 antidepressants: pharmacovigilance analysis of 31,688 reports from the WHO Spontaneous Reporting Database. Drug Saf. 2022;45:1539\u201349. https:\/\/doi.org\/10.1007\/s40264-022-01246-4.","journal-title":"Drug Saf"},{"key":"1058_CR17","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","volume":"28","author":"M Gatti","year":"2021","unstructured":"Gatti M, Antonazzo IC, Diemberger I, De Ponti F, Raschi E. Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system. Eur J Prev Cardiol. 2021;28:983\u20139. https:\/\/doi.org\/10.1177\/2047487320915663.","journal-title":"Eur J Prev Cardiol"},{"key":"1058_CR18","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.3390\/cancers13081758","volume":"13","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Thromboembolic events with cyclin-dependent kinase 4\/6 inhibitors in the FDA Adverse Event Reporting System. Cancers (Basel). 2021;13:1758. https:\/\/doi.org\/10.3390\/cancers13081758.","journal-title":"Cancers (Basel)"},{"key":"1058_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186:219\u201327. https:\/\/doi.org\/10.1007\/s10549-020-06001-w.","journal-title":"Breast Cancer Res Treat"},{"key":"1058_CR20","unstructured":"FDA. FAERS Quarterly Data Extract Files. 2021. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 3 May 2021."},{"key":"1058_CR21","doi-asserted-by":"publisher","DOI":"10.1101\/2023.06.07.23291076","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Giunchi V, Battini V, Puligheddu S, Khouri C, Carnovale C, et al. Standardization of drug names in the FDA adverse event reporting system: the DiAna dictionary. medRxiv. 2023. https:\/\/doi.org\/10.1101\/2023.06.07.23291076.","journal-title":"medRxiv"},{"key":"1058_CR22","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2042098616685010","volume":"8","author":"M Hauben","year":"2017","unstructured":"Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8:145\u201356. https:\/\/doi.org\/10.1177\/2042098616685010.","journal-title":"Ther Adv Drug Saf."},{"key":"1058_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.therap.2019.01.006","volume":"74","author":"JL Faillie","year":"2019","unstructured":"Faillie JL. Case-non-case studies: principle, methods, bias and interpretation. Therapie. 2019;74:225\u201332. https:\/\/doi.org\/10.1016\/j.therap.2019.01.006.","journal-title":"Therapie"},{"key":"1058_CR24","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1111\/bcp.14459","volume":"87","author":"M Gatti","year":"2021","unstructured":"Gatti M, Fusaroli M, Caraceni P, Poluzzi E, De Ponti F, Raschi E. Serious adverse events with tocilizumab: pharmacovigilance as an aid to prioritize monitoring in COVID-19. Br J Clin Pharmacol. 2021;87:1533\u201340. https:\/\/doi.org\/10.1111\/bcp.14459.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR25","doi-asserted-by":"publisher","first-page":"265","DOI":"10.5772\/50095","volume":"12","author":"E Poluzzi","year":"2012","unstructured":"Poluzzi E, Raschi E, Piccinni C, De F. Data mining techniques in pharmacovigilance: analysis of the publicly accessible FDA Adverse Event Reporting System (AERS). Data Min Appl Eng Med InTech. 2012;12:265\u2013302. https:\/\/doi.org\/10.5772\/50095.","journal-title":"Data Min Appl Eng Med InTech"},{"key":"1058_CR26","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jclinepi.2023.08.010","volume":"162","author":"L Gaucher","year":"2023","unstructured":"Gaucher L, Sabatier P, Katsahian S, Jannot AS. Pharmacovigilance studies without a priori hypothesis systematic review highlights inappropriate multiple testing correction procedures. J Clin Epidemiol. 2023;162:127\u201334. https:\/\/doi.org\/10.1016\/j.jclinepi.2023.08.010.","journal-title":"J Clin Epidemiol"},{"key":"1058_CR27","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1111\/bcp.15802","volume":"89","author":"CA Gravel","year":"2023","unstructured":"Gravel CA, Douros A. Considerations on the use of different comparators in pharmacovigilance: a methodological review. Br J Clin Pharmacol. 2023;89:2671\u20136. https:\/\/doi.org\/10.1111\/bcp.15802.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR28","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble JM. Active-comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2023;89:431\u20139. https:\/\/doi.org\/10.1111\/bcp.15178.","journal-title":"Br J Clin Pharmacol"},{"key":"1058_CR29","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00228-014-1658-1","volume":"70","author":"B Grundmark","year":"2014","unstructured":"Grundmark B, Holmberg L, Garmo H, Zethelius B. Reducing the noise in signal detection of adverse drug reactions by standardizing the background: a pilot study on analyses of proportional reporting ratios-by-therapeutic area. Eur J Clin Pharmacol. 2014;70:627\u201335. https:\/\/doi.org\/10.1007\/s00228-014-1658-1.","journal-title":"Eur J Clin Pharmacol"},{"key":"1058_CR30","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1177\/2042098616685010","volume":"8","author":"M Hauben","year":"2017","unstructured":"Hauben M, Hung E, Wood J, Soitkar A, Reshef D. The impact of database restriction on pharmacovigilance signal detection of selected cancer therapies. Ther Adv Drug Saf. 2017;8:145\u201356. https:\/\/doi.org\/10.1177\/2042098616685010.","journal-title":"Ther Adv Drug Saf"},{"key":"1058_CR31","unstructured":"European Medicines Agency. Designated Medical Event (DME) list. 2020. https:\/\/www.ema.europa.eu\/documents\/other\/designated-medical-event-dme-list_en.xls. Accessed 17 Mar 2022."},{"key":"1058_CR32","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1097\/CAD.0000000000001191","volume":"33","author":"X Li","year":"2022","unstructured":"Li X, Chen G, Hu Y, Zhao B, Jiang J. Caution the arrhythmia association with antibody-dr]ug conjugates: a pharmacovigilance study. Anticancer Drug. 2022;33:226\u201334. https:\/\/doi.org\/10.1097\/CAD.0000000000001191.","journal-title":"Anticancer Drug"},{"key":"1058_CR33","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1080\/17512433.2022.2121705","volume":"15","author":"Z Ma","year":"2022","unstructured":"Ma Z, Zhang Y, Zhu M, Feng L, Zhang Y, An Z. Interstitial lung disease associated with anti-HER2 anti-body drug conjugates: results from clinical trials and the WHO\u2019s Pharmacovigilance database. Expert Rev Clin Pharmacol. 2022;15:1351\u201361. https:\/\/doi.org\/10.1080\/17512433.2022.2121705.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1058_CR34","doi-asserted-by":"publisher","first-page":"967017","DOI":"10.3389\/fphar.2022.967017","volume":"13","author":"S Xia","year":"2022","unstructured":"Xia S, Zhao Y, Guo L, Gong H, Wang Y, Ma R, et al. Do antibody-drug conjugates increase the risk of sepsis in cancer patients? A pharmacovigilance study. Front Pharmacol. 2022;13:967017. https:\/\/doi.org\/10.3389\/fphar.2022.967017.","journal-title":"Front Pharmacol"},{"key":"1058_CR35","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/onco.13878","volume":"26","author":"LM Spring","year":"2021","unstructured":"Spring LM, Nakajima E, Hutchinson J, Viscosi E, Blouin G, Weekes C, et al. Sacituzumab govitecan for metastatic triple-negative breast cancer: clinical overview and management of potential toxicities. Oncologist. 2021;26:827\u201334. https:\/\/doi.org\/10.1002\/onco.13878.","journal-title":"Oncologist"},{"key":"1058_CR36","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1200\/JCO.2017.77.6211","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy BE, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology and Infectious Diseases Society of America Clinical Practice Guideline Update. J Clin Oncol. 2018;36:1443\u201353. https:\/\/doi.org\/10.1200\/JCO.2017.77.6211.","journal-title":"J Clin Oncol"},{"key":"1058_CR37","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1200\/JCO.18.00374","volume":"36","author":"RA Taplitz","year":"2018","unstructured":"Taplitz RA, Kennedy BE, Bow EJ, Crews J, Gleason C, Hawley DK, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. J Clin Oncol. 2018;36:3043\u201354. https:\/\/doi.org\/10.1200\/JCO.18.00374.","journal-title":"J Clin Oncol"},{"key":"1058_CR38","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1200\/JOP.18.00269","volume":"15","author":"AJ Zimmer","year":"2019","unstructured":"Zimmer AJ, Freifeld AG. Optimal management of neutropenic fever in patients with cancer. J Oncol Pract. 2019;15:19\u201324. https:\/\/doi.org\/10.1200\/JOP.18.00269.","journal-title":"J Oncol Pract"},{"key":"1058_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1016\/S1470-2045(17)30312-1","volume":"18","author":"V Di\u00e9ras","year":"2017","unstructured":"Di\u00e9ras V, Miles D, Verma S, Pegram M, Welslau M, Baselga J, et al. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2017;18:732\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(17)30312-1.","journal-title":"Lancet Oncol"},{"key":"1058_CR40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40264-021-01069-9","volume":"44","author":"FA Lievano","year":"2021","unstructured":"Lievano FA, Scarazzini LJ, Tyczynski JE, Schubert CM. Renz CL Risk minimization of antibody-drug conjugates in oncology: a review. Drug Saf. 2021;44:733\u201342. https:\/\/doi.org\/10.1007\/s40264-021-01069-9.","journal-title":"Drug Saf"},{"key":"1058_CR41","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1016\/j.numecd.2018.02.014","volume":"28","author":"E Raschi","year":"2018","unstructured":"Raschi E, Poluzzi E, Salvo F, Pariente A, De Ponti F, Marchesini G, et al. Pharmacovigilance of sodium-glucose co-transporter-2 inhibitors: what a clinician should know on disproportionality analysis of spontaneous reporting systems. Nutr Metab Cardiovasc Dis. 2018;28:533\u201342. https:\/\/doi.org\/10.1016\/j.numecd.2018.02.014.","journal-title":"Nutr Metab Cardiovasc Dis"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-024-01058-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-024-01058-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T09:22:11Z","timestamp":1716369731000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-024-01058-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["1058"],"URL":"https:\/\/doi.org\/10.1007\/s11523-024-01058-9","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"24 March 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"C.Z. has received grants from Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, Teva, Seagen, Eli Lilly, Celgene, MSD, GSK, Amgen, and Daiichi; has received support for attending meetings and\/or travel from Novartis, Roche, Pfizer, PharmaMar, Tesaro, Pierre Fabre, Ist. Gentili, and Celgene; and has participated in data safety monitoring or advisory boards for Novartis, Roche, Eisai, AstraZeneca, Pfizer, PharmaMar, Amgen, Tesaro, Quintiles IMS, Eli Lilly, Celgene, MSD, GSK, and Daiichi. L.G. reports serving as a consultant\/advisor for Lilly, Novartis, AstraZeneca, GlaxoSmithKline, and Incyte. S.C., S.P., M.F., M.Y., F.D.P., and E.R. have no conflicts of interest that are directly relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The datasets analyzed during the current study are available in the public domain:\n                      \n                      .","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Codes are available upon reasonable request to the authors.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"S.C. conceived the study. E.R., M.F., S.P., and S.C. contributed to study design. S.P. and M.F. contributed to the acquisition and analysis of data. S.C. drafted the manuscript. All authors contributed to the interpretation of data, critically revised the manuscript, and provided final approval.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}},{"value":"This article does not contain any studies with human participants performed by any of the authors. This study is based on anonymous data that can be downloaded from a publicly available source. Therefore, no ethical approval is required.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}